logo
Plus   Neg
Share
Email

Seattle: TUKYSA Approved In Switzerland To Treat HER2-positive Breast Cancer

Seattle Genetics, Inc. (SGEN) announced the Swiss Agency for Therapeutic Products has granted approval for TUKYSA tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast cancer. The application for TUKYSA approval was reviewed by Swissmedic as part of Project Orbis, an initiative of the U.S. FDA Oncology Center of Excellence.

On April 17, the FDA approved TUKYSA in the U.S. under the FDA's Real-Time Oncology Review pilot program, and represented the first new drug approved under Project Orbis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT